Effect analysis of sacubitril and valsartan in the treatment of patients with chronic heart failure with reduced ejection fraction
Objective To evaluate the clinical effect of sacubitril and valsartan in the treatment of patients with chronic heart failure with reduced ejection fraction.Methods 70 patients with chronic heart failure with reduced ejection fraction were divided into a control group and an observation group according to randomized number table method,with 35 cases in each group.The control group was treated with routine western medicine symptomatic support,and the observation group was treated with sacubitril and valsartan on the basis of the control group.Patients in both groups were compared in terms of clinical efficacy,adverse reactions,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],inflammatory factors[tumor necrosis factor-α(TNF-α),nuclear factor-κB(NF-κB)]before and after treatment.Results The total effective rate of the observation group was 94.29%,which was higher than 74.29%of the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group was similar(P>0.05).Before treatment,LVEF,LVESD and LVEDD were similar in the two groups(P>0.05).After treatment,LVEF,LVESD and LVEDD in both groups were improved compared with those before treatment;the observation group had LVESD of(38.65±3.05)mm and LVEDD of(50.22±5.02)mm,which were lower than(44.08±3.10)and(56.22±5.30)mm in the control group;LVEF of(46.46±4.02)%in the observation group was higher than(40.60±3.50)%in the control group(P<0.05).Before treatment,the levels of TNF-α and NF-κB were similar in the two groups(P>0.05).After treatment,TNF-α,NF-κB in both groups were improved compared with those before treatment;the observation group had TNF-α of(10.20±2.02)ng/L and NF-κB of(24.28±2.26)pg/ml,which were lower than(12.95±2.20)ng/L and(30.15±2.70)pg/ml in the control group(P<0.05).Conclusion Sacubitril and valsartan has definite effect on patients with chronic heart failure with reduced ejection fraction,which can promote the improvement of cardiac function and inflammatory factors in patients,and has high drug safety.
Reduced ejection fractionChronic heart failureSacubitril and valsartanCardiac function
万方数据
维普
